According To The WHO Remdesivir Proved Ineffective In Covid-19 Treatment

Remdesivir Proved Ineffective

The recently published article, on this website, on Remdesivir that was fact-checked and considered legitimate at the time, has now been proven to be ineffective. WHO’s recent study proved that Remdesivir has little effect on COVID patients.

Gilead Science Inc antiviral medication recently gained traction after it was used to treat the President of the USA, Donald Trump. The drug had also received an emergency use authorization from the USA FDA and it has since been in use in many countries.

However, WHO’s recent “Solidarity” trials examined four potential drug treatments which included Remdesivir, hydroxychloroquine, anti-HIV drug combination lopinavir/ritonavir, and interferon, in 11,266 adult patients across more than 30 countries.

The Remdesivir, as stated in the previous article is supposed to reduce the amount of time on supplemental oxygen and reduce the hospital stay by at least 5 days. The WHO study has disproved this fact stating it made no effect on the 28-day mortality rate either.

The WHO study is still in its preliminary stages and is yet to be evaluated, however, it’s been uploaded on the preprint server medRxiv

The Gilead study had tested the effects of Remdesivir against placebo. The study showed the treatment cut COVID-19 recovery time by five days compared with patients who got a placebo in a trial comprising 1,062 patients.

“The emerging (WHO) data appears inconsistent, with more robust evidence from multiple randomized, controlled studies published in peer-reviewed journals validating the clinical benefit of Remdesivir,” Gilead told Reuters.

“We are concerned the data from this open-label global trial has not undergone the rigorous review required to allow for constructive scientific discussion, particularly given the limitations of the trial design.”

WHO chief scientist Soumya Swaminathan said that hydroxychloroquine and lopinavir/ritonavir proved ineffective and were stopped in June, but trials for the same have continued in 30 other countries. Swaminathan said that they’re looking ahead and are looking for other antiviral drugs that may prove effective.

Also Read